337 related articles for article (PubMed ID: 28642816)
1. Safe and effective administration of T-VEC in a patient with heart transplantation and recurrent locally advanced melanoma.
Schvartsman G; Perez K; Flynn JE; Myers JN; Tawbi H
J Immunother Cancer; 2017; 5():45. PubMed ID: 28642816
[TBL] [Abstract][Full Text] [Related]
2. Positron emission tomography/computed tomography evaluation of oncolytic virus therapy efficacy in melanoma.
Franke V; van der Hiel B; van de Wiel BA; Klop WMC; Ter Meulen S; van Akkooi ACJ
Eur J Cancer; 2018 Feb; 90():149-152. PubMed ID: 29224902
[No Abstract] [Full Text] [Related]
3. The safety of talimogene laherparepvec for the treatment of advanced melanoma.
Gangi A; Zager JS
Expert Opin Drug Saf; 2017 Feb; 16(2):265-269. PubMed ID: 27989216
[TBL] [Abstract][Full Text] [Related]
4. Talimogene laherparepvec (T-VEC) in advanced melanoma: complete response in a heart and kidney transplant patient. A case report.
Ressler J; Silmbrod R; Stepan A; Tuchmann F; Cicha A; Uyanik-Ünal K; Hoeller C
Br J Dermatol; 2019 Jul; 181(1):186-189. PubMed ID: 30776080
[TBL] [Abstract][Full Text] [Related]
5. Talimogene laherparepvec (T-VEC) as cancer immunotherapy.
Kohlhapp FJ; Zloza A; Kaufman HL
Drugs Today (Barc); 2015 Sep; 51(9):549-58. PubMed ID: 26488034
[TBL] [Abstract][Full Text] [Related]
6. Talimogene Laherparepvec: An Oncolytic Virus Therapy for Melanoma.
Corrigan PA; Beaulieu C; Patel RB; Lowe DK
Ann Pharmacother; 2017 Aug; 51(8):675-681. PubMed ID: 28351167
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic drug evaluation of talimogene laherparepvec for the treatment of advanced melanoma.
Burke EE; Zager JS
Expert Opin Drug Metab Toxicol; 2018 Apr; 14(4):469-473. PubMed ID: 29557682
[TBL] [Abstract][Full Text] [Related]
8. Talimogene laherparepvec treatment to overcome loco-regional acquired resistance to immune checkpoint blockade in tumor stage IIIB-IV M1c melanoma patients.
Fröhlich A; Niebel D; Fietz S; Egger E; Buchner A; Sirokay J; Landsberg J
Cancer Immunol Immunother; 2020 May; 69(5):759-769. PubMed ID: 32052079
[TBL] [Abstract][Full Text] [Related]
9. Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1-derived oncolytic immunotherapy.
Harrington KJ; Puzanov I; Hecht JR; Hodi FS; Szabo Z; Murugappan S; Kaufman HL
Expert Rev Anticancer Ther; 2015; 15(12):1389-403. PubMed ID: 26558498
[TBL] [Abstract][Full Text] [Related]
10. An Update on the Role of Talimogene Laherparepvec (T-VEC) in the Treatment of Melanoma: Best Practices and Future Directions.
Larocca CA; LeBoeuf NR; Silk AW; Kaufman HL
Am J Clin Dermatol; 2020 Dec; 21(6):821-832. PubMed ID: 32767272
[TBL] [Abstract][Full Text] [Related]
11. Engineered oncolytic viruses to treat melanoma: where are we now and what comes next?
Rothermel LD; Zager JS
Expert Opin Biol Ther; 2018 Dec; 18(12):1199-1207. PubMed ID: 30392405
[TBL] [Abstract][Full Text] [Related]
12. Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma.
Bommareddy PK; Patel A; Hossain S; Kaufman HL
Am J Clin Dermatol; 2017 Feb; 18(1):1-15. PubMed ID: 27988837
[TBL] [Abstract][Full Text] [Related]
13. Intratumoral Immunotherapy-Update 2019.
Hamid O; Ismail R; Puzanov I
Oncologist; 2020 Mar; 25(3):e423-e438. PubMed ID: 32162802
[TBL] [Abstract][Full Text] [Related]
14. Biodistribution, shedding, and transmissibility of the oncolytic virus talimogene laherparepvec in patients with melanoma.
Andtbacka RHI; Amatruda T; Nemunaitis J; Zager JS; Walker J; Chesney JA; Liu K; Hsu CP; Pickett CA; Mehnert JM
EBioMedicine; 2019 Sep; 47():89-97. PubMed ID: 31409575
[TBL] [Abstract][Full Text] [Related]
15. The role of talimogene laherparepvec (T-VEC) in the age of checkpoint inhibitors.
Andtbacka RH
Clin Adv Hematol Oncol; 2016 Aug; 14(8):576-9. PubMed ID: 27487099
[No Abstract] [Full Text] [Related]
16. Complete intracranial response to talimogene laherparepvec (T-Vec), pembrolizumab and whole brain radiotherapy in a patient with melanoma brain metastases refractory to dual checkpoint-inhibition.
Blake Z; Marks DK; Gartrell RD; Hart T; Horton P; Cheng SK; Taback B; Horst BA; Saenger YM
J Immunother Cancer; 2018 Apr; 6(1):25. PubMed ID: 29622046
[TBL] [Abstract][Full Text] [Related]
17. Talimogene laherparepvec (T-Vec) for the treatment of melanoma and other cancers.
Grigg C; Blake Z; Gartrell R; Sacher A; Taback B; Saenger Y
Semin Oncol; 2016 Dec; 43(6):638-646. PubMed ID: 28061981
[TBL] [Abstract][Full Text] [Related]
18. Kaposi's varicelliform eruption in a patient with metastatic melanoma and primary cutaneous anaplastic large cell lymphoma treated with talimogene laherparepvec and nivolumab.
Miller DM; Trowbridge RM; Desai A; Drews RE
J Immunother Cancer; 2018 Nov; 6(1):122. PubMed ID: 30454071
[TBL] [Abstract][Full Text] [Related]
19. First Oncolytic Viral Therapy for Melanoma.
Poh A
Cancer Discov; 2016 Jan; 6(1):6. PubMed ID: 26552414
[TBL] [Abstract][Full Text] [Related]
20. Talimogene Laherparepvec (T-VEC) for the Treatment of Advanced Locoregional Melanoma After Failure of Immunotherapy: An International Multi-Institutional Experience.
Carr MJ; Sun J; DePalo D; Rothermel LD; Song Y; Straker RJ; Baecher K; Louie RJ; Stahlie EHA; Wright GP; Naqvi SMH; Kim Y; Sarnaik AA; Karakousis GC; Lowe MC; Delman KA; van Akkooi ACJ; Ollila DW; Collichio F; Zager JS
Ann Surg Oncol; 2022 Feb; 29(2):791-801. PubMed ID: 34648098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
